The Pulmonary Fibrosis Foundation (PFF), which supports research that advance understanding and better ways of treating pulmonary fibrosis (PF), is calling for submissions for next year’s PFF Scholars program for emerging scientists. Program winners will receive up to $50,000 over two years for PF research that may ultimately lead…
Leaders in the U.S. rare disease community came together recently for a webinar to present helpful information on how to start a nonprofit and patient registry. They shared about how their respective organizations came to be, as well as the benefits of creating patient registries and how they can help…
A first patient has been enrolled in a proof-of-concept Phase 2 trial of C21 (VP01), Vicore Pharma’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF) and other lung diseases. “We are pleased to announce that we can now start our IPF trial despite the ongoing COVID-19…
The Pulmonary Fibrosis Foundation (PFF) plans to launch “Pinpoint PF,” an educational and awareness campaign for those at risk of pulmonary fibrosis (PF) or showing symptoms, in December. “We introduced the campaign … during the PFF’s virtual Volunteer Meeting and received an enthusiastic response from our PFF Ambassadors…
Newly developed therapies may hold promise for the treatment of pulmonary fibrosis, as described in two studies. The therapies, which are expected to move into clinical trials in the next several months, were both developed by Purdue University scientists in Indiana, led by Philip…
The National Heart, Lung and Blood Institute, part of the National Institutes of Health, has granted $920,000 to a team of researchers at the University at Buffalo (UB) to develop a model that mimics human lung tissue. The researchers say their model should offer an accurate and rapid…
Esbriet (pirfenidone) or Ofev (nintedanib) treatment in adults with idiopathic pulmonary fibrosis (IPF) led to changes in blood markers reflecting reduced systemic inflammation and oxidative stress after 24 weeks of therapy, a small study found. …
Bridge Biotherapeutics and Boehringer Ingelheim ended a collaboration and license agreement to develop BBT-877, a potential treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders. The companies entered into an agreement in July 2019 and, although no details were provided about its termination, the…
Galapagos and OncoArendi Therapeutics have entered into an exclusive agreement for the global development and commercialization of OncoArendi’s OATD-01, an investigational treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Lung diseases like IPF are characterized by increased activity of enzymes called…
Use of the well-known anticoagulant therapy warfarin in people with idiopathic pulmonary fibrosis (IPF) is associated with reduced transplant-free survival, but direct oral anticoagulants (DOACs) are not, a study found. While…
Get regular updates to your inbox.
